Abstract The renin-angiotensin system (RAS) is a coordinated hormonal cascade intimately involved in cardiovascular and renal control and blood pressure regulation. Angiotensin II (Ang II), the major RAS effector peptide, binds two distinct receptors, the angiotensin type-1 receptor (AT 1 R) and the angiotensin type-2 (AT 2 R) receptor. The vast majority of the physiological actions of Ang II, almost all of them detrimental, are mediated by AT 1 Rs. In contrast, AT 2 Rs negatively modulate the actions of AT 1 Rs under the majority of circumstances and generally possess beneficial effects. AT 2 Rs induce vasodilation in both resistance and capacitance vessels, mediating natriuresis directly and via interactions with dopamine D1 receptors in the renal proximal tubule. AT 2 Rs inhibit renin biosynthesis and secretion and protect the kidneys from inflammation and ischemic injury. Our understanding of the exact role of AT 2 Rs in physiology and pathophysiology continues to expand; the purpose of this review is to provide an up-to-date summary of the functional role of AT 2 Rs at the organ, tissue, cellular, and subcellular levels with emphasis on the vascular and renal actions that bear on blood pressure regulation and hypertension.
Introduction
The renin-angiotensin system (RAS) is a coordinated hormonal cascade involved in cardiovascular control, with angiotensin II (Ang II) as the main effector peptide regulating blood pressure [16] . Ang II binds two distinct RAS receptors, the angiotensin type-1 receptor (AT 1 R) and the angiotensin type-2 (AT 2 R) receptor, with high affinity [16, 18] . The vast majority of the physiological actions of Ang II are mediated by AT 1 Rs, including cellular dedifferentiation and proliferation; vasoconstriction; reduction of vascular compliance; cardiac contractility; increased renal tubule sodium (Na + ) reabsorption; aldosterone, vasopressin, and endothelin secretion; salt appetite; thirst; and activation of the sympathetic nervous system [16, 18] . In contrast, AT 2 Rs negatively modulate the actions of AT 1 Rs under the majority of circumstances [14, 16, 18, 35] . However, our understanding of the exact role of AT 2 Rs in physiology and pathophysiology continues to expand. The purpose of this review is to provide an up-to-date summary of these actions.
AT 2 R Expression
The AT 2 R is a 7-transmembrane G protein-coupled receptor composed of 363 amino acids (molecular weight 41,220 Da) with only 34 % sequence homology with the AT 1 R [18] . The sequence homology between the two receptors occurs mainly in the transmembrane hydrophobic regions of the molecules which form their 7-transmembrane helical columns [18] .
AT 2 Rs are expressed ubiquitously at very high levels in the fetus but decline precipitously in the neonatal period in most, but not all, tissues [18, 79] . Although there is relatively low expression of AT 2 Rs compared to AT 1 Rs in adult tissues, AT 2 Rs are expressed in the adult kidney, adrenal cortex, heart, and vasculature and predominate over AT 1 Rs in specific sites such as the uterus, ovary, adrenal medulla, and discrete areas of the brain [42, 44, 72, 79] .
Cell signaling mechanisms of AT 2 Rs
AT 2 R signaling mechanisms differ markedly from those of AT 1 Rs. As shown in Fig. 1 , AT 2 R activation initiated via binding of Ang II to the receptor on the plasma membrane triggers G protein coupling through Giα2 and Giα3 via the third intracellular loop of the receptor. This signal initiates the activation of phosphotyrosine phosphatases, whose function is to dephosphorylate and thus inactivate mitogen-activated protein (MAP) kinases such as extracellular-regulated kinase (ERK)-1 and ERK-2. Phosphotyrosine phosphatase activation can also occur via a G protein-independent mechanism. In any case, MAP kinase inhibition opposes MAP kinase activation as a result of AT 1 R activation. This fundamental difference in cell signaling at the MAP kinase level is thought to form the basis for the counter-regulatory action of AT 2 Rs opposing at least some of the actions of AT 1 Rs [14, 16, 18, 35] .
AT 2 R stimulation can also activate lipid signaling pathways including increased phospholipase A 2 activity and arachidonic acid release [35] . Long-term activation of AT 2 Rs by Ang II can also increase the biosynthesis of ceramides, which in turn can activate stress kinases and caspases to induce apoptosis [35] .
A major AT 2 R signaling pathway, involved in almost all of the reported physiologic actions of AT 2 Rs, is the bradykinin (BK)-nitric oxide (NO)-cyclic guanosine 3′,5′-monophosphate (cGMP) signaling cascade as described in more detail later.
Vascular actions of AT 2 Rs
There is now overwhelming evidence that AT 2 Rs oppose the AT 1 R-mediated vasoconstrictor action of Ang II [4, 6, 15, 19, 27, 32, 36, 50, 57, 58, 62, 63, 74, 77] . AT 2 R-mediated vasodilation has been demonstrated in small resistance arteries of the mesenteric, uterine, adrenal, coronary, and peripheral circulations in a wide variety of animal models and in humans [4, 6, 15, 19, 27, 36, 50, 57, 58, 62, 63, 74] . Vasodilation due to AT 2 R activation has also been demonstrated in large capacitance vessels such as the aorta [32, 77] and in the fetal circulation [50] . AT 2 R-induced vasodilation is mediated by activation of the vasodilator cascade composed of BK, NO, and cGMP [60, 61, 65] . AT 2 Rs increase the production of NO and cGMP either by stimulating increased BK production with a subsequent effect mediated through BK B 2 receptors or by direct activation of NO production independent of BK [1, 64, 69] (Fig. 2) .
The AT 2 R-mediated vasodilator action of Ang II is most easily demonstrated when AT 1 Rs have been inhibited using an Ang (AT 1 ) receptor blocker (ARB) [14, 15, 27, 63, 74] . For example, chronic Ang II administration induces hypotension in AT 1 R-blocked rats and this response is abolished by coadministration of AT 2 R antagonist PD-123319 (PD; Fig. 3 ). This is likely to be related to the predominance of AT 1 R over AT 2 R expression in blood vessels [7, 73] . The vasodilator effects mediated by AT 2 Rs are also facilitated when RAS is activated-for example, by dietary Na + restriction, Ang II infusion, or in renovascular hypertension [8, 62, 63] . In all instances, AT 2 Rs are upregulated, augmenting the vasodilator response to Ang II [8, 44, 62] . Other conditions which upregulate AT 2 Rs also elicit its vasodilator actions, such as increased pressure load due to aortic banding [32, 77] . In such studies, suprarenal abdominal aortic banding results in a marked (300 %) increase in vascular AT 2 R mRNA. AT 2 R blockade with specific AT 2 R antagonist PD-123319 (PD) or
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Opposes MAP kinase activation via AT 1 Rs Fig. 1 [32, 77] . The ninefold increase in aortic cGMP stimulated by Ang II in pressure-loaded aortas is also abolished by PD or icatibant. These studies underscore the potential importance of AT 2 R upregulation in circulatory disorders that trigger counter-regulatory depressor mechanisms mediated by BK and NO. The vasodilator and hypotensive effects of AT 2 R activation are both acute and of long term and are not associated with desensitization, making the AT 2 Rs a potential therapeutic target in hypertension [15, 74] . Studies have also demonstrated that the blood pressure-lowering effects of AT 1 R blockade with an ARB might be mediated, at least in part, by AT 2 R activation [62, 63] . Indeed in a study of resistance arteries in diabetic, hypertensive human subjects, chronic ARB administration upregulated vascular AT 2 Rs and facilitated a vasodilator response to Ang II in vitro [58] . Similarly, in the presence of AT 1 R blockade, direct pharmacological AT 2 R activation with Compound 21 (a highly selective non-peptide AT 2 R agonist) resulted in depressor responses in spontaneously hypertensive rats [9] (Fig. 4) . These studies indicate the potential therapeutic value of a non-peptide AT 2 R agonist in combination with an ARB in the treatment of hypertension and other cardiovascular disorders.
The role of AT 2 Rs in the vasculature has recently expanded to include insight into the contribution of AT 2 Rs in the progression of aortic aneurysms. In a mouse model of Marfan's syndrome, loss of AT 2 R expression accelerates the aberrant growth and rupture of the aorta [22] . Selective AT 1 R blockade abrogated aneurysm progression, but only when AT 2 R-induced attenuation of ERK phosphorylation remained intact [22] . This study highlights the protective nature of intact AT 2 R signaling in aortic aneurysm progression.
Renal actions of AT 2 Rs
AT 2 Rs mediate natriuresis AT 2 Rs are expressed throughout the kidney in both vascular and tubular elements and are heavily expressed in renal proximal tubule cells [42, 44] . Definitive evidence that AT 2 Rs mediate natriuresis has now been produced [45, 48, 53] . This was achieved by using the technique of direct renal interstitial microinfusion of pharmacological agents, enabling the evaluation of renal function selectively, without the influence of systemic hemodynamic or hormonal changes. Selective intrarenal AT 1 R blockade in rats induced a highly significant natriuretic response that was abolished with intrarenal co-infusion of the AT 2 R-specific antagonist PD [45] . These results further indicate that, similar to vasodilation, the beneficial natriuretic response to ARB administration is related to AT 2 R activation. Because des-aspartyl 1 -Ang II (Ang III) is highly active at AT 2 Rs in the brain [51] , a study was conducted to investigate whether Ang III might be an agonist for AT 2 R-mediated responses in the kidney [45] . When systemic AT 1 Rs were blocked, direct intrarenal Ang III infusion induced a highly significant increase in renal Na + excretion that was abolished by concurrent AT 2 R blockade with PD. Similar to vascular responses, intrarenal Ang III infusion alone demonstrated no effect on renal Na + excretion in the absence of systemic AT 1 R blockade [45] .
Surprisingly, in the presence of systemic AT 1 R blockade, intrarenal administration of Ang II, even at substantially higher molar equivalent concentrations than with Ang III, was unable to induce natriuresis [45] . To explain this observation, it was hypothesized that Ang II needs to be converted to Ang III to interact with AT 2 Rs in the kidney. Ang II is converted to Ang III by aminopeptidase A (APA), and Ang III is converted to hexapeptide angiotensin IV (Ang IV) by aminopeptidase N (APN) (Fig. 5 ). In the presence of systemic AT 1 R blockade, intrarenal infusion of Ang III engendered a natriuretic response, which was markedly augmented by intrarenal coinfusion of the APN inhibitor 2-amino-4-methylsulfonyl-butane-thiol, methane-thiol (PC-18) [48] . The augmentation in Ang III-induced natriuresis due to APN inhibition was also abolished by intrarenal AT 2 R blockade with PD [48] (Fig. 6 ). Intrarenal infusion of Ang II induced a natriuretic response only in the presence of APN inhibition. These results indicate that Ang III is the preferred AT 2 R agonist in the regulation of renal Na + excretion. These studies are potentially important for disease states such as diabetes mellitus and obesity, wherein AT 2 Rs are upregulated in renal proximal tubule cells, inhibit Na + /K + ATPase (NKA), and reduce Na + transport [23, 26] . The inhibition of NKA is mediated via a NO/cGMP-dependent pathway [24] , and inhibition of NAD(P)H oxidase potentiates AT 2 R-mediated natriuresis [52] .
Recent in vivo studies have demonstrated that renal AT 2 Rs mediate natriuresis via a NO/cGMP signaling cascade operating in the renal proximal tubule [37] . In vitro studies have also recently shown that renal AT 2 Rs decrease AT 1 R function in the proximal tubule by the common NO/ cGMP pathway and also decrease AT 1 R expression at the transcriptional level via the ubiquitous transcription factor Sp1 [75] . AT 2 Rs also were shown upon activation with a ligand to heterodimerize with AT 1 Rs, reducing their expression level via a direct protein-protein interaction at the cell surface [75] . Therefore, renal AT 2 Rs may oppose AT 1 Rs via several signaling pathways.
Recent studies have also demonstrated that AT 2 Rs may induce natriuresis in part through an action in the thick ascending limb of Henle (TAL) [29, 34] . Ang II increases NO production in TALs via activation of AT 2 Rs. In turn, NO inhibits the Na + /K + /2Cl − co-transporter and reduces Na + reabsorption in TALs [34] . Interestingly, this effect of AT 2 Rs is diminished in Dahl salt-sensitive rats, which has been widely employed as a model of salt-sensitive hypertension. In addition, the defect in the ability of TALs to respond to AT 2 R activation could be overcome with a higher dose of the AT 2 R peptide agonist CGP42112A [34] . This observation suggests that AT 2 R activation may provide therapeutic benefit for salt-sensitive hypertension. Reexamination of this effect using the newer non-peptide AT 2 R agonist Compound 21 would be of interest in confirming these findings. The renal dopaminergic system is a crucial system in the control of renal Na + excretion and blood pressure [13] . Dopamine (DA) is synthesized from filtered L-dihydroxyphenylalanine taken up into proximal tubule cells (Fig. 7) . DA is exported from the proximal tubule cell largely into the tubule lumen, where it binds to the D 1 -like receptor family (D 1 and D 5 subtypes). D 1 -like receptor (D 1LIKE R) activation inhibits Na + reabsorption through an adenylate cyclase-cAMP-dependent mechanism. The importance of the renal dopaminergic system is underscored by the fact that renal D 1LIKE receptors account for about 50 % of basal Na + excretion under normal-high Na + intake [13] . Exogenous administration of fenoldopam, a highly selective D 1LIKE R agonist in animals and humans, elicits a major natriuretic response that is based almost exclusively upon the inhibition of proximal tubule Na + reabsorption [13] . It has been demonstrated that intrarenal fenoldopam administration induces a highly significant natriuresis in the sodiumloaded rat [53] . The natriuretic response is blocked completely by SCH-23390, a highly selective D 1LIKE R antagonist. However, surprisingly, the natriuretic response to fenoldopam is also abolished by concomitant intrarenal administration of AT 2 receptor antagonist PD [53] (Fig. 8) .
To explore the possible mechanism of AT 2 R involvement in D 1 -like receptor-induced natriuresis, studies were performed to determine intracellular AT 2 R trafficking in renal proximal tubule cells [34] . Fenoldopam administration in vivo was accompanied by translocation of AT 2 Rs from intracellular sites to the apical plasma membranes of renal proximal tubule cells (Fig. 9) [47] . Neither total [53] nor basolateral proximal tubule cell AT 2 R expression was changed in response to fenoldopam infusion [47] , suggesting that apically distributed AT 2 Rs participated in the natriuretic response. Previous experiments have established that D 1LIKE Rs translocate to the cell surface in response to D 1LIKE R activation in cultured kidney cells, kidney section preparations, and isolated proximal tubules [11, 33, 38] and that this response requires an intact microtubule network [38] . Recently, these findings have been extended to the natriuretic mechanism of renal AT 2 Rs in vivo. Fenoldopam-induced natriuresis and AT 2 R translocation to the apical plasma membrane are completely abolished during intrarenal co-infusion of nocodazole, which disrupts the microtubule network but preserves the actin microfilaments of renal proximal tubule cells [49] . Thus, microtubules are necessary not only for D 1LIKE R recruitment but also for AT 2 R recruitment in response to fenoldopam, suggesting a common pathway for the natriuretic function of these receptors.
Furthermore, since D 1LIKE Rs signal through cAMP/ protein kinase A to mediate natriuresis, the role of RI cAMP generation in AT 2 R-mediated natriuresis was also investigated in vivo [47] . Renal interstitial accumulation of cAMP via direct activation of adenylyl cyclase with forskolin and selective inhibition of cAMP degradation with 3-isobutyl-1-methylxanthine (IBMX) caused a significant and sustained increase in AT 2 R-mediated natriuresis. Direct agonist stimulation of D 1LIKE Rs was not necessary for AT 2 R-mediated natriuresis since forskolin + IBMX-induced natriuresis persisted in the presence of D 1LIKE R blockade with SCH-23390 [47] . Thus, one mechanism by which AT 2 Rs and D 1LIKE Rs interact in high Na + conditions to mediate natriuresis is related to D 1LIKE R-cAMP signaling, which, in turn, provides the stimulus necessary for AT 2 R translocation and natriuresis (Fig. 10) . Because the effect is independent of specific D 1LIKE R-induced activation of adenylyl cyclase, activation of other receptors that signal through cAMP/protein kinase A pathway may be advantageous in promoting AT 2 R-mediated natriuresis in vivo. Indeed administration of parathyroid hormone, through its cAMP/protein kinase A-dependent but not phospholipase C/protein kinase Cdependent signaling, has been shown to redistribute Na + transporters such as Na + -hydrogen exchanger-3 and inhibit Na + -K + -ATPase activity in a direction favoring natriuresis and diuresis [78] . Renal AT 2 Rs are known to inhibit Na + -K + -ATPase activity [24] , and increased renal cAMP may regulate this process.
AT 2 Rs suppress renin biosynthesis and secretion
Ang II participates in a so-called short-loop negative feedback suppression of renin biosynthesis and secretion through AT 1 Rs on renal juxtaglomerular cell plasma membranes [16] . This mechanism functions as a physiological "brake" to prevent the potential detrimental actions of high levels of circulating Ang II mediated through AT 1 Rs. Studies have demonstrated that, similar to AT 1 Rs, AT 2 Rs also contribute to renin suppression in response to high Ang II levels [66] . Furthermore, in obese Zucker rats, chronic AT 2 R antagonism with PD resulted in a 13-mmHg increase in mean arterial pressure, and a threefold increase in renin expression in the kidney cortex [59] . These data suggest that renal AT 2 Rs serve a protective role against increases in blood pressure, in part due to AT 2 R-mediated renin suppression. One of the first studies to examine the role of renal AT 2 Rs in ischemic damage subjected AT 2 R transgenic (AT 2 R-Tg) and wild-type mice to five sixth (5/6) nephrectomy, a model of ischemic renal injury [28] . In AT 2 R-Tg mice, glomerular expression of AT 2 Rs was upregulated by 5/6 nephrectomy. Urinary albumin excretion was decreased by about one third in AT 2 R-Tg mice compared to that in wild-type mice. AT 2 RTg mice had a significant reduction in transforming growth factor-β and platelet-derived growth factor. Urinary excretion of NO metabolites was increased 2.5-fold in AT 2 R-Tg mice. All of the aforementioned responses were blocked by AT 2 R antagonist, PD. Thus, AT 2 R over-expression protected glomeruli from injury in the 5/6 nephrectomy model. 30 days after renal ablation. Animals pre-treated with AT 1 R antagonist, losartan, showed a further increase in AT 2 R expression. AT 2 R antagonist PD was associated with down-regulation of AT 2 Rs, increased renal damage, and increased blood pressure in the 5/6 nephrectomy model. Both of these studies suggest that AT 2 R represents a beneficial counter-regulatory mechanism to protect the kidney from ischemic injury.
AT 2 Rs protect kidneys from inflammation
Consistent with the aforementioned protection from ischemic injury, AT 2 R activation also protects the kidneys from inflammatory changes induced by AT 1 Rs in renovascular hypertension [3, 41] . AT 1 R activation is well known to induce inflammation via stimulation of a variety of inflammatory molecules, including interleukin (IL)-6, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β, and induction of oxidative stress [39] . 2K1C Goldblatt hypertensive animals develop early inflammation in the ischemic kidney with increased renal production of TNF-α, IL-6, and TGF-β and reduction of NO and cGMP in ischemic kidneys followed by progressive fibrosis [41] . Direct pharmacological activation of AT 2 Rs with nonpeptide-selective agonist Compound 21 abolished the inflammatory process associated with reduction of inflammatory markers and improvement in renal NO and cGMP levels [41] . Interestingly, AT 2 R activation was coupled to increased AT 2 R expression in the ischemic kidneys. AT 1 R activation also induces signal transducer and activator of transcription proteins 3 (STAT3), which in turn mediate inflammation. Other studies [3] have shown in cells expressing AT 2 Rs but not AT 1 Rs (PC12W cells) that stimulation of AT 2 Rs reduces STAT 3 phosphorylation and TNF-α production and that this response can be blocked with AT 2 R antagonist PD-123319. Taken altogether, these findings suggest that AT 2 R activation may become part of a therapeutic strategy to prevent and/or reverse inflammation in cardiovascular and renal disease.
Relative angiotensin peptide affinities for AT 2 R
It is increasingly recognized that angiotensin I (Ang I) metabolites, other than Ang II, can exert biological activity. The peptides include the C-terminal breakdown products of Ang II, namely, the heptapeptide Ang III and the hexapeptide Ang IV, as well as the N-terminal heptapeptide angiotensin 1-7 (Ang 1-7) . In most instances, these peptides induce cardiovascular effects that are opposite to the classical effects of Ang II [17, 45, [54] [55] [56] . For example, chronic treatment with Ang 1-7 has been reported to evoke both AT 2 R-mediated vaso-and athero-protective effects in apoliproprotein E-deficient mice [68] . Likewise, in the kidney, while Ang II is known to cause sodium reabsorption via actions at the AT 1 R, Ang III induces AT 2 R-mediated natriuresis [45] . When the degradation of Ang III is inhibited, this effect is enhanced, both in the presence [48] and absence of systemic AT 1 R blockade [37] . Further studies using APA (EC-33) and APN (PC-18) inhibitor combinations (Fig. 5 ) have indicated that intrarenal Ang II must be converted to Ang III in order to observe AT 2 R-mediated natriuresis [46] , suggesting that this heptapeptide is the preferred agonist of AT 2 R-mediated natriuresis. In addition to the kidney, two other cardiovascular hormonal systems have been linked to Ang III as the preferred agonist for AT 2 Rs, the coronary vascular bed and the adrenal zona glomerulosa. In the coronary microcirculation, Ang III, rather than Ang II, is the preferred ligand to induce AT 2 R-mediated vasodilation [70] . Ang III is also the preferred agonist for AT 2 R-mediated aldosterone secretion from the adrenal cortex [76] .
A recent systematic in vitro study performed in human embryonic kidney cells examined the relative AT 2 R binding affinities and selectivities of a number of endogenous angiotensin peptides [10] . Affinity is defined by the IC 50 value of a ligand for an individual receptor, whereas selectivity refers to the ratio of IC 50 values of a ligand at two different receptors. Thus, ligands can have a similar affinity but different selectivities. While Ang III demonstrated a similar affinity for AT 2 Rs as Ang II, it had at least 30-fold selectivity for AT 2 Rs over AT 1 Rs. Moreover, while Ang 1-7 and Ang IV exhibited~500-and~100-fold reduced affinity for AT 2 Rs compared with Ang II, these peptides were 40-and 200-fold more selective for AT 2 Rs than AT 1 Rs [10] . Collectively, these AT 2 R affinity profiling results provide further evidence for the functional data pinpointing Ang III as the preferred agonist of AT 2 Rs in certain tissues. The precise molecular conformation that renders Ang III a better fit within the AT 2 R binding pocket awaits further investigation.
Novel intracrine (nuclear and mitochondrial) AT 2 R actions
While the RAS in the past was regarded as an exclusively circulating hormonal (endocrine) system, recent evidence has identified several local tissue RASs that function independently of the circulating system [16] . These local systems function at the cell-to-different cell (paracrine) and/or cell-to-same cell (autacrine) levels and are now considered crucial regulators in physiology and pathophysiology. In the periphery, local hormonal systems have been identified in the kidney, heart, and blood vessels, among several other tissues and organs. At present, the exact role of AT 2 Rs in these paracrine and autacrine RAS actions is largely unknown. However, recent studies have identified AT 2 Rs as important signal transducers at the subcellular level, potentially contributing to important actions of a completely intracellular (intracrine) RAS. Recent interest has been focused on two intracellular organelles, nuclei and mitochondria.
Regarding nuclear Ang receptors, AT 2 Rs do not contain a canonical nuclear localization sequence as AT 1 Rs do. In spite of this, AT 2 Rs are highly expressed in renal cortical nuclei of fetal and adult sheep and in response to Ang II release NO, likely from nuclear endothelial NOS activation [20] . Since soluble gualylyl cyclase has been identified in isolated nuclei, it is possible that cGMP production may increase in response to nuclear AT 2 R activation. BK also has been shown to induce NO production in isolated nuclei and therefore may be involved in intranuclear AT 2 R signaling [21] . As evidence of a functional role for nuclear AT 2 Rs, AT 2 R antagonist PD-123319 augmented the generation of reactive oxygen species in response to Ang II in isolated nuclei. As a non-peptide highly selective AT 2 R agonist, Compound 21 should cross the plasma and nuclear membranes and have access to the intracellular and nuclear compartments [67] . If the intracellular RAS has a role in cardiovascular and renal pathophysiology, targeting of the nuclear RAS pathway may convey additional benefits to those of extracellular inhibition.
Regarding mitochondrial Ang receptors, neither AT 1 Rs nor AT 2 Rs have a consensus targeting sequence for mitochondria. However, recent studies have demonstrated that, while AT 1 Rs are not expressed, AT 2 Rs are heavily localized to the inner mitochondrial membranes where they colocalize with Ang II [2] . Activation of AT 2 Rs in isolated mitochondria dose-dependently increased NO production, a response that was abolished with AT 2 R antagonist PD-123319 [2] . Importantly, AT 2 R activation was accompanied by inhibition of oxygen consumption (respiration) that was reversed by NOS inhibitor L-NAME [2] . Furthermore, during the process of aging, there was a significant increase in AT 1 R and decrease in AT 2 R mitochondrial expression. This balance was reversed with chronic treatment with an AT 1 R antagonist, suggesting that AT 1 R antagonist and/or AT 2 R agonist treatment might hold promise for prevention of the chronic disease burden of aging [2] . Indeed it has been shown that disruption of AT 1 Rs promotes longevity in mice and hypertensive rats, an effect that could be related to increased AT 2 R expression and/or activation [5, 40] .
Sex differences in AT 2 R responses
AT 2 Rs are encoded on the X-chromosome, suggesting the possibility that females may have increased expression of AT 2 Rs as compared to males. Indeed AT 2 R expression was enhanced in female mice accompanied by decreased inflammation, cell proliferation, and oxidative stress in response to injury compared to male mice [43] . However, in AT 2 R-null female mice, vascular injury was enhanced. Moreover, treatment with an AT 1 R blocker had a more beneficial effect in female than male wild-type mice. These results indicated that sex differences in response to vascular injury could be related at least in part to exaggerated AT 2 R expression in females.
Female Sprague-Dawley rats also have enhanced AT 2 Rmediated renal vasodilator and tubuloglomerular feedback responses compared to males [12] . In females, this difference did not translate to renal Na + excretion, which was identical in male and female rats; that is, AT 2 R activation caused a similar increase in Na + excretion via an action at the renal tubule in both male and female Sprague-Dawley rats [30, 31] . In addition, AT 2 R activation directly inhibits renal tubule Na + -K + ATPase activity both in male obese Zucker rats and in male Sprague-Dawley rats [24, 25] . Furthermore, AT 2 R activation induces natriuresis via a renal tubule mechanism in male Sprague-Dawley rats [52] . Thus, there is ample evidence in the literature that renal tubule AT 2 R activation induces natriuresis similarly in both male and female rats.
Summary and conclusions
In summary, the cardiovascular and renal actions of AT 2 Rs generally oppose those mediated by AT 1 Rs. At the level of cell signaling, AT 2 Rs inhibit MAP kinases ERK-1 and -2, reducing or nullifying AT 1 R-mediated increases in ERK activity. The BK-NO-cGMP pathway is now recognized as the extracellular AT 2 R signaling pathway relevant to the majority of AT 2 R actions and is a candidate intracellular mediator as well. From a functional standpoint, AT 2 Rs induce systemic vasodilation and natriuresis, the latter of which appears to be mediated by endogenous Ang III rather than Ang II. AT 2 R inhibition of renal tubule Na + transport occurs largely in the proximal tubule and also to some extent in the thick ascending limb of Henle. Natriuresis induced by renal dopamine via D 1 Rs in the proximal tubule requires cAMP-stimulated translocation and activation of AT 2 Rs at the plasma membrane. Characterization of intracellular (intracrine) RASs is currently focusing on the potential role of AT 2 Rs as predominant effectors in nuclei and mitochondria.
In conclusion, AT 2 Rs play a beneficial counter-regulatory role in cardiovascular and renal function. Reduced AT 2 R expression and/or activity may contribute to the initiation/ aggravation of disease processes such as hypertension, edema-forming states, and inflammation/fibrosis, leading to cardiovascular and renal tissue damage. Many of the beneficial effects of AT 1 R blockade are attributable at least in part to increased AT 2 R expression and activation. In the future, pharmacologic AT 2 R activation holds promise to provide a therapeutic advantage or even a preventive strategy alone or combined with concurrent AT 1 R blockade. Recent findings suggest the possibility that AT 2 R activation may offer limited protection from the aging process and/or its accompanying chronic diseases. Whether the increased longevity observed with AT 1 R ablation may be related at least in part to AT 2 R activation constitutes an exciting area of future investigation.
